IBA acquires PETLinQ, takes on Hickey as prez of molecular tracers

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
IBA Molecular has acquired PETLinQ, an education and software technologies company serving the hospital, outpatient radiology, PET and nuclear medicine marketplace.

PETLinQ provides a suite of products and services for imaging, workflow and education for PET and PET/CT imaging centers, said the Louvain-la-Neuve, Belgium-based IBA.

IBA Molecular North America also announced that Michael Hickey, long-time executive with AstraZeneca, has been named president of IBA’s Molecular Tracers North America division. He will be based in Dulles, Va., and report to Renaud Dehareng, president of IBA Molecular Tracers Worldwide.

Manjula Puthenedam, PhD,

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.